These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9611906)

  • 1. Cost-effectiveness of cardiovascular prevention programs in Spain.
    Plans-Rubió P
    Int J Technol Assess Health Care; 1998; 14(2):320-30. PubMed ID: 9611906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of statins in the primary prevention of cardiovascular disease: a systematic review and economic analysis for Belgium.
    Neyt M; De Laet C; Van Brabandt H; Franco O; Ramaekers D
    Acta Cardiol; 2009 Feb; 64(1):1-10. PubMed ID: 19317290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cost-effectiveness of hypertension treatment in Catalonia (Spain)].
    Plans Rubió P; Tresserras Gaju R; Navas Alcalá E; Pardell Alentá H
    Med Clin (Barc); 2002 Feb; 118(6):211-6. PubMed ID: 11864543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of treatments to reduce cholesterol levels, blood pressure and smoking for the prevention of coronary heart disease: evaluative study carried out in Spain.
    Plans-Rubió P
    Pharmacoeconomics; 1998 May; 13(5 Pt 2):623-43. PubMed ID: 17165328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of full coverage of the medical management of smoking cessation in France.
    Chevreul K; Cadier B; Durand-Zaleski I; Chan E; Thomas D
    Tob Control; 2014 May; 23(3):223-30. PubMed ID: 23197369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost Effectiveness of Free Access to Smoking Cessation Treatment in France Considering the Economic Burden of Smoking-Related Diseases.
    Cadier B; Durand-Zaleski I; Thomas D; Chevreul K
    PLoS One; 2016; 11(2):e0148750. PubMed ID: 26909802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of dietary treatment of hypercholesterolemia in Spain.
    Rubió PP
    Public Health; 1997 Jan; 111(1):33-40. PubMed ID: 9033222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of hypertension therapy according to 2014 guidelines.
    Moran AE; Odden MC; Thanataveerat A; Tzong KY; Rasmussen PW; Guzman D; Williams L; Bibbins-Domingo K; Coxson PG; Goldman L
    N Engl J Med; 2015 Jan; 372(5):447-55. PubMed ID: 25629742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan.
    Tsutani K; Igarashi A; Fujikawa K; Evers T; Kubin M; Lamotte M; Annemans L
    Intern Med; 2007; 46(4):157-62. PubMed ID: 17301509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health Benefits and Cost-Effectiveness of Asymptomatic Screening for Hypertension and High Cholesterol and Aspirin Counseling for Primary Prevention.
    Dehmer SP; Maciosek MV; LaFrance AB; Flottemesch TJ
    Ann Fam Med; 2017 Jan; 15(1):23-36. PubMed ID: 28376458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care settings: a multinational comparison.
    Cornuz J; Gilbert A; Pinget C; McDonald P; Slama K; Salto E; Paccaud F
    Tob Control; 2006 Jun; 15(3):152-9. PubMed ID: 16728744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT).
    Atthobari J; Asselbergs FW; Boersma C; de Vries R; Hillege HL; van Gilst WH; Gansevoort RT; de Jong PE; de Jong-van den Berg LT; Postma MJ;
    Clin Ther; 2006 Mar; 28(3):432-44. PubMed ID: 16750458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands.
    Boersma C; Carides GW; Atthobari J; Voors AA; Postma MJ
    Clin Ther; 2007 May; 29(5):963-971. PubMed ID: 17697915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is it cost-effective to increase aspirin use in outpatient settings for primary or secondary prevention? Simulation data from the REACH Registry Australian Cohort.
    Ademi Z; Liew D; Hollingsworth B; Steg PG; Bhatt DL; Reid CM;
    Cardiovasc Ther; 2013 Feb; 31(1):45-52. PubMed ID: 21884025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000-2010.
    Fidan D; Unal B; Critchley J; Capewell S
    QJM; 2007 May; 100(5):277-89. PubMed ID: 17449875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of ramipril in patients at high risk for cardiovascular events : economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the Statutory Health Insurance perspective.
    Schädlich PK; Brecht JG; Rangoonwala B; Huppertz E
    Pharmacoeconomics; 2004; 22(15):955-73. PubMed ID: 15449961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of statin therapy for the primary prevention of coronary heart disease.
    Walshe V; Nash A; Barry M
    Ir Med J; 2006 May; 99(5):144-5. PubMed ID: 16892920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation of primary prevention of cardiovascular diseases in mild hypertension: a scenario analysis for the Netherlands.
    Stevanović J; O'Prinsen AC; Verheggen BG; Schuiling-Veninga N; Postma MJ; Pechlivanoglou P
    Clin Ther; 2014 Mar; 36(3):368-84.e5. PubMed ID: 24534654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study.
    Feenstra TL; Hamberg-van Reenen HH; Hoogenveen RT; Rutten-van Mölken MP
    Value Health; 2005; 8(3):178-90. PubMed ID: 15877590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.